(RTTNews) – GSK plc (GSK, GSK.L) issued an update on FDA advisory committee review of Blenrep combinations for patients with relapsed/refractory multiple myeloma. GSK said it remains confident in the benefit/risk profile of Blenrep or belantamab mafodotin-blmf and will continue t